NICE recommends Galapagos' Jyseleca in UC

Belgian biotech Galapagos (AMS: GLPG) has announced that the UK's National Institute of Health and Clinical Excellence (NICE) has recommended the use of Jyseleca (filgotinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) when other treatments have not been successful.

This means that, from today, Jyseleca will be available for eligible patients across England, Wales and Northern Ireland on the National Health Service (NHS).

"As a once-daily tablet, the medicine provides an option for people to manage their condition in their own home"Jimmy Limdi, consultant gastroenterologist at the Northern Care Alliance NHS Foundation Trust and the University of Manchester, said: “Today’s recommendation from NICE regarding use of filgotinib in UC is excellent news for patients and healthcare professionals looking after people living with UC.